Tenecteplase (TNK) is a medication used to break up blood clots. In this trial, it is being studied for treating central retinal artery occlusion (CRAO), which is a blockage in the blood vessel that supplies the retina. The medication works by helping to dissolve the clot that is blocking blood flow to the eye.

Aspirin (ASA) is a common blood-thinning medication that helps prevent blood clots from forming. It works by making blood platelets less sticky, which reduces the chance of clots forming in blood vessels. In this trial, it serves as an active comparison treatment for patients with central retinal artery occlusion.

Central Retinal Artery Occlusion – A condition where blood flow through the central retinal artery becomes blocked, cutting off blood supply to the retina. The blockage typically occurs when a blood clot or piece of fatty deposit (embolus) gets lodged in the artery. The retina, which is the light-sensitive tissue at the back of the eye, becomes deprived of oxygen and nutrients. This condition usually develops suddenly and affects one eye at a time. The lack of blood flow causes the retinal cells to become damaged, leading to vision problems in the affected eye. Vision loss typically occurs in the central field of vision while peripheral vision may remain intact.